Epstein-barr virus-induced posttransplant lymphoproliferative disorders

Carlos V. Paya; John J. Fung; Michael A. Nalesnik; Elliott Kieff; Michael Green; Gregory Gores; Thomas M. Habermann; Russell H. Wiesner; Lode J. Swinnen; E. Steve Woodle; Jonathan S. Bromberg

doi:10.1097/00007890-199911270-00015

Epstein-barr virus-induced posttransplant lymphoproliferative disorders

Carlos V. Paya, John J. Fung, Michael A. Nalesnik, Elliott Kieff, Michael Green, Gregory Gores, Thomas M. Habermann, Russell H. Wiesner, Lode J. Swinnen, E. Steve Woodle, Jonathan S. Bromberg

Research output: Contribution to journal › Article › peer-review

440 Scopus citations

Abstract

Epstein-Barr virus-induced posttransplant lymphoproliferative disease (EBV-PTLD) continues to be a major complication after solid organ transplantation in high-risk patients. Despite the identification of risk factors that predispose patients to develop EBV-PTLD, limitations in our knowledge of its pathogenesis, variable criteria for establishing the diagnosis, and lack of randomized studies addressing the prevention and treatment of EBV-PTLD hamper the optimal management of this transplant complication. This review summarizes the current knowledge of EBV-PTLD and, as a result of two separate international meetings on this topic, and provides recommendations for future areas of study.

Original language	English (US)
Pages (from-to)	1517-1525
Number of pages	9
Journal	Transplantation
Volume	68
Issue number	10
DOIs	https://doi.org/10.1097/00007890-199911270-00015
State	Published - Nov 27 1999

ASJC Scopus subject areas

Transplantation

Access to Document

10.1097/00007890-199911270-00015

Cite this

@article{8a3a734c5a6344528387b3fbaa3bd667,

title = "Epstein-barr virus-induced posttransplant lymphoproliferative disorders",

abstract = "Epstein-Barr virus-induced posttransplant lymphoproliferative disease (EBV-PTLD) continues to be a major complication after solid organ transplantation in high-risk patients. Despite the identification of risk factors that predispose patients to develop EBV-PTLD, limitations in our knowledge of its pathogenesis, variable criteria for establishing the diagnosis, and lack of randomized studies addressing the prevention and treatment of EBV-PTLD hamper the optimal management of this transplant complication. This review summarizes the current knowledge of EBV-PTLD and, as a result of two separate international meetings on this topic, and provides recommendations for future areas of study.",

author = "Paya, {Carlos V.} and Fung, {John J.} and Nalesnik, {Michael A.} and Elliott Kieff and Michael Green and Gregory Gores and Habermann, {Thomas M.} and Wiesner, {Russell H.} and Swinnen, {Lode J.} and Woodle, {E. Steve} and Bromberg, {Jonathan S.}",

year = "1999",

month = nov,

day = "27",

doi = "10.1097/00007890-199911270-00015",

language = "English (US)",

volume = "68",

pages = "1517--1525",

journal = "Transplantation",

issn = "0041-1337",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

TY - JOUR

T1 - Epstein-barr virus-induced posttransplant lymphoproliferative disorders

AU - Paya, Carlos V.

AU - Fung, John J.

AU - Nalesnik, Michael A.

AU - Kieff, Elliott

AU - Green, Michael

AU - Gores, Gregory

AU - Habermann, Thomas M.

AU - Wiesner, Russell H.

AU - Swinnen, Lode J.

AU - Woodle, E. Steve

AU - Bromberg, Jonathan S.

PY - 1999/11/27

Y1 - 1999/11/27

N2 - Epstein-Barr virus-induced posttransplant lymphoproliferative disease (EBV-PTLD) continues to be a major complication after solid organ transplantation in high-risk patients. Despite the identification of risk factors that predispose patients to develop EBV-PTLD, limitations in our knowledge of its pathogenesis, variable criteria for establishing the diagnosis, and lack of randomized studies addressing the prevention and treatment of EBV-PTLD hamper the optimal management of this transplant complication. This review summarizes the current knowledge of EBV-PTLD and, as a result of two separate international meetings on this topic, and provides recommendations for future areas of study.

AB - Epstein-Barr virus-induced posttransplant lymphoproliferative disease (EBV-PTLD) continues to be a major complication after solid organ transplantation in high-risk patients. Despite the identification of risk factors that predispose patients to develop EBV-PTLD, limitations in our knowledge of its pathogenesis, variable criteria for establishing the diagnosis, and lack of randomized studies addressing the prevention and treatment of EBV-PTLD hamper the optimal management of this transplant complication. This review summarizes the current knowledge of EBV-PTLD and, as a result of two separate international meetings on this topic, and provides recommendations for future areas of study.

UR - http://www.scopus.com/inward/record.url?scp=0033610627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033610627&partnerID=8YFLogxK

U2 - 10.1097/00007890-199911270-00015

DO - 10.1097/00007890-199911270-00015

M3 - Article

C2 - 10589949

AN - SCOPUS:0033610627

SN - 0041-1337

VL - 68

SP - 1517

EP - 1525

JO - Transplantation

JF - Transplantation

IS - 10

ER -

Epstein-barr virus-induced posttransplant lymphoproliferative disorders

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this